Ocumension Therapeutics (HKG:1477) expects revenue to come between 408 million yuan and 420 million yuan for the year ended Dec. 31, up to 70.5% higher compared with the 246.4 million yuan in the previous year, according to a Wednesday filing with the Hong Kong bourse.
The company attributed the increase in revenue to an increase in sales of its corr lle products' among other factors.